Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|142|8|1712-1722

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.142, Iss.8, 2018-04, pp. : 1712-1722

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How attractive is the combination of a sodium glucose co‐transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 613-615

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sodium–glucose cotransporter 2 inhibitors and renal function钠‐葡萄糖共转运体2抑制剂与肾功能

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 3, 2015-05 ,pp. : 295-298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 591-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 984-993

John Wiley & Sons Inc

Access to resources Recommend Favorite

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 984-993

John Wiley & Sons Inc

Access to resources Recommend Favorite